Abiomed Pumps Cash Into Eleventh-Hour Bid For Thermo CardioSystems
This article was originally published in The Gray Sheet
Executive Summary
Abiomed may be able to leverage its strength in the capital markets - specifically, an enhanced cash position resulting from a $95 mil. secondary offering last March - to undercut a previously announced all-stock bid by Thoratec for ventricular assist device developer Thermo CardioSystems.